TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma.

ABSTRACT:

Background

The ten-eleven translocation 1 (TET1), which is essential for active DNA demethylation, plays a multifaceted role in the pathogenesis of colorectal cancer. The study has demonstrated the association of TET1 mutations with a high response to immune checkpoint inhibitors (ICIs) in diverse cancers. However, the relationship between TET1 mutations and the response to ICIs in colon cancer is still lacking.

Methods

The prognosis, predictive markers, immune characteristics, mutation number of DNA damage repair (DDR) pathways, pathway enrichment, and drug sensitivity conditions were all compared between TET1-mutated and wild-type patients with colon adenocarcinoma (COAD).

Results

The overall survival of patients with TET1 mutations in the ICI-treated cohort was sig

SUBMITTER: Qiu T 

PROVIDER: S-EPMC8991851 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature